ERLEADA® for Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)

In the SPARTAN study in patients with non-metastatic CRPC:

ERLEADA® + ADT improved median metastasis-free survival (MFS) by YEARS (24.3 months) vs placebo + ADT1

(40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)

SPARTAN Primary Publication

Review the journal article to learn more about the study results

Accessing this article may require a subscription to The New England Journal of Medicine.


Exploratory Analysis

SPARTAN Patient-Reported Outcomes Publication

Review the journal article to learn more about patient-reported outcomes in the SPARTAN study

Accessing this article may require a subscription to The Lancet Oncology.

ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; HR = hazard ratio; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.

Reference

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.